01—Abstract
Summary
Summary of the 10-Q filed October 28, 2025. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported strong third-quarter 2025 results in its Form 10-Q.
Total revenues for the three months ended September 30, 2025 were $794.9 milliona, up from $622.1 million a year earlier, and net income was $209.5 million, versus $129.8 million. For the first nine months, total revenues were $2.06 billion and net income was $324.9 million. Net product sales of INGREZZA were $686.6 million in the quarter and $1.86 billion year-to-date, while CRENESSITY, launched in December 2024, contributed $98.1 million in the quarter and $165.8 million year-to-date.
The company attributed the growth to strong patient demand for INGREZZA, partially offset by lower net price from new market access investments, and to CRENESSITY's launch. Operating expenses rose as the company invested in its commercial organization and pipeline. Research and development expense was $250.0 millionb in the quarter versus $195.0 million, driven by Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia.
Selling, general, and administrative expense was $291.6 millionc versus $234.3 million. Cash, cash equivalents and marketable securities totaled $2.11 billion at September 30, 2025, and cash flow from operations was $394.3 million for the nine months. The company repurchased $167.7 million of stock in the first nine months under its 2025 program, with $332.3 million remaining.
The filing also flags legal and regulatory matters that investors should monitor. These include patent litigation against Zydus over a generic version of INGREZZA SPRINKLE, a civil investigative demand from the U.S. Department of Justice in August 2025 related to INGREZZA sales and marketing, and an FDA untitled letter regarding INGREZZA promotional claims. The filing also notes a Phase 3 study of valbenazine for adjunctive schizophrenia treatment did not meet its primary endpoint, and that customer concentration is high, with four customers representing over 90%d of gross product sales.
02—Key points
Key Highlights
- Total revenues of $794.9 million in Q3 2025, up from $622.1 million in Q3 2024; net income of $209.5 million versus $129.8 million.
- INGREZZA net product sales of $686.6 million in Q3 2025 (versus $612.9 million) and $1.86 billion for the first nine months; CRENESSITY net product sales of $98.1 million in the quarter and $165.8 million year-to-date.
- Diluted EPS of $2.04 in Q3 2025 versus $1.24 a year earlier; nine-month diluted EPS of $3.19 versus $2.29.
- R&D expense rose to $250.0 million in Q3 2025 from $195.0 million, reflecting Phase 3 investment in osavampator (MDD) and direclidine (schizophrenia).
- Cash, cash equivalents and marketable securities of $2.11 billion at September 30, 2025, versus $1.82 billion at December 31, 2024.
- Repurchased $167.7 million of common stock in the first nine months of 2025; $332.3 million remained under the $500.0 million 2025 Repurchase Program.
- Risk items include a DOJ civil investigative demand (August 2025) on INGREZZA sales and marketing, Paragraph IV patent litigation against Zydus, and a Phase 3 valbenazine adjunctive schizophrenia study that missed its primary endpoint.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2025, Neurocrine Biosciences kept $0.26.
- Revenue$794.9M100.0%
- Cost of revenue−$14.0M1.8%
- Gross profit$780.9M98.2%
- Operating costs−$541.9M68.2%
- Operating income$239.0M30.1%
- Interest, other & tax−$29.5M3.7%
- Net income$209.5M26.4%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2025filed October 28, 2025Financial Statements
Q3 FY2025 against Q3 FY2024
| Line item | Q3 FY2025Q3 FY2024 | Change |
|---|---|---|
| Revenue | $794.90M$622.10M | +27.8% |
| Cost of Revenue | $14.00M$8.00M | +75.0% |
| Gross Profit | $780.90M$614.10M | +27.2% |
| SG&A Expenses | $291.60M$234.30M | +24.5% |
| Operating Expenses | $555.90M$438.30M | +26.8% |
| Operating Income | $239.00M$183.80M | +30.0% |
| Net Income | $209.50M$129.80M | +61.4% |
| EPS (Basic) | $2.11$1.28 | +64.8% |
| EPS (Diluted) | $2.04$1.24 | +64.5% |
| Shares Outstanding (Basic) | 99.40M101.10M | −1.7% |
| Shares Outstanding (Diluted) | 102.50M104.30M | −1.7% |
05—Questions
Frequently Asked Questions
What drove revenue growth in the third quarter of 2025?
Net product sales rose to $789.9 million from $616.6 million, driven by INGREZZA ($686.6 million, up from $612.9 million) and CRENESSITY ($98.1 million, launched in December 2024). The filing notes INGREZZA growth reflected strong patient demand, partially offset by lower net price due to new market access investments.
How much did operating expenses increase, and why?
Total operating expenses were $555.9 million in Q3 2025 versus $438.3 million a year earlier. R&D rose to $250.0 million, mainly on Phase 3 programs for osavampator and direclidine, and SG&A rose to $291.6 million from $234.3 million, reflecting commercial organization investment and CRENESSITY launch activities.
What legal and regulatory matters does the filing disclose?
The company is pursuing patent litigation against Zydus over a generic version of INGREZZA SPRINKLE. In August 2025 it received a civil investigative demand from the U.S. Department of Justice regarding INGREZZA sales and marketing, which it is cooperating with. In September 2025 it received an FDA Office of Prescription Drug Promotion untitled letter alleging certain INGREZZA promotional claims are misleading. The company believes its advertising complies with applicable laws.
How concentrated are the company's customers?
Four customers represent over 90% of total gross product sales. Customer A accounted for 41% of gross product sales in the first nine months of 2025 (44% a year earlier), and 45% of accounts receivable at September 30, 2025.
What is the company's liquidity position?
Cash, cash equivalents and marketable securities totaled $2.11 billion at September 30, 2025, and working capital was $1.52 billion. Operating cash flow was $394.3 million for the first nine months of 2025. Management believes resources are sufficient for at least the next 12 months.
06—Continue